spiro[cyclohexanyl-1',2-(3-amino)-1H-quinoxaline] | 1241960-88-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: spiro[cyclohexanyl-1',2-(3-amino)-1H-quinoxaline]
• 英文别名: spiro[4H-quinoxaline-3,1'-cyclohexane]-2-amine
• CAS: 1241960-88-2
• 化学式: C₁₃H₁₇N₃
• 分子量: 215.298
• InChiKey: DJTKDISTLUHMKA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  16
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  50.4
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  在 三乙胺 作用下， 以 对二甲苯 为溶剂， 反应 3.0h， 以80%的产率得到spiro[cyclohexanyl-1',2-(3-amino)-1H-quinoxaline]
  参考文献：
  名称：

  Application of Secondary Amines in the Synthesis of Some New Spiro Heterocyclic Compounds

  摘要：

  1-Anilinocycloalkanecarbonitriles 1a-c were prepared and reacted with active methylene reagents to give compounds 5a-c through 10a-c and reacted with different other reagents such as benzaldehyde, ethyl aminoacetate, ethyl mercaptoacetate, or hydrazine carbothioamide, which afforded the desired spiro heterocycles compounds 11a-c through 14a-c.

  DOI：

  10.1080/10426500802713283

文献信息

• Spiropyrazine derivatives as inhibitors of non-apoptotic regulated cell-death
  申请人：Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)

  公开号：US10647687B2

  公开（公告）日：2020-05-12

  The present invention relates to spiropyrazine compounds which are inhibitors of non-apoptotic regulated cell death, and to pharmaceutical compositions containing such compounds. Furthermore, the present invention relates to the use of such compounds and pharmaceutical compositions in therapy, in particular in the treatment of a condition, disorder or disease that is characterised by non-apoptotic regulated cell-death or where non-apoptotic regulated cell-death is likely to play or plays a substantial role. The compounds and pharmaceutical compositions described herein are also useful in the treatment of a condition, disorder or disease that is characterised by oxidative stress or where oxidative stress is likely to play or plays a substantial role; and/or a condition, disorder or disease that is characterised by activation of (1) one or more components of the necrosome; (2) death domain receptors; and/or (3) Toll-like receptors; and/or (4) players in ferroptotic/ferroptosis signalling, or where activation of any one of (1) to (3) and/or (4) is likely to play or plays a substantial role.

  本发明涉及作为非凋亡调节细胞死亡抑制剂的螺吡嗪化合物，以及含有此类化合物的药物组合物。此外，本发明还涉及此类化合物和药物组合物在治疗中的用途，特别是在治疗以非凋亡调节性细胞死亡为特征或非凋亡调节性细胞死亡可能起作用或起重要作用的病症、紊乱或疾病中的用途。本文所述的化合物和药物组合物还可用于治疗以氧化应激为特征的病症、紊乱或疾病，或氧化应激可能起作用或起重要作用的病症、紊乱或疾病；和/或(1)坏死体的一种或多种成分；(2)死亡结构域受体；和/或(3)Toll 样受体；和/或(4)铁变态反应/铁变态反应信号的参与者，或(1)至(3)和/或(4)中任何一种的激活可能起或起重要作用的情况、紊乱或疾病。
• US9802956B2
  申请人：——

  公开号：US9802956B2

  公开（公告）日：2017-10-31
• USRE48992E1
  申请人：——

  公开号：USRE48992E1

  公开（公告）日：2022-03-29